Clinical Trial

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Study acronym: PROPHETIC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2019-08-13; most recent amendment 2025-10-12.
Status change: Recruiting → Active, Not Recruiting 2025-10-12
Status change: Not Yet Recruiting → Recruiting 2019-10-22
Trial Details
NCT Number NCT04056247
Lead Sponsor OncoHost Ltd.
Conditions Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma
Enrollment 10,000 participants
Start Date 2019-10-01
Primary Completion 2029-10-01 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-15